Grants Search Results

The University of Illinois at Chicago, Rush University Medical Center, and John H. Stroger Hospital of Cook County Program exists to meet the needs of an extremely diverse population who currently struggle with cancer or who have survived this terrible disease but are at great risk for many long-term health problems. UIC, Rush, and Stroger Medical Centers anchor the near west side of Chicago and serve incredibly vulnerable patients and families, the majority of whom have very limited personal resources, medical knowledge, and English language skills. This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant is named for the Do It for Dominic Fund which honors the memory of Dominic Cairo who battled non-Hodgkins lymphoma and was a hero to his school and community. His family and friends continue to raise funds and support research in the hopes that no child has to go through what Dominic endured.

This grant supports a the nurse researchers in the University of Illinois at Chicago (UIC), Rush University Medical Center, and John H. Stroger Hospital of Cook County COG Clinical Trials Program to ensure more kids can be treated on clinical trials, often their best hope for a cure.

This grant is named for the Do It for Dominic Fund which honors the memory of Dominic Cairo who battled non-Hodgkins lymphoma and was a hero to his school and community. His family and friends continue to raise funds and support research in the hopes that no child has to go through what Dominic endured.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Precision–based Therapy for Childhood Leukemia. For a description of this project, see the consortium grant made to the lead institution: Dana–Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

Modern therapies such as stem cell transplant and immune therapy have made high-risk neuroblastoma a survivable disease for some children, but little is known about the chronic health issues experienced by survivors. In order to ensure that future treatments address both the chance and the quality of cure, this consortium aims to examine the impact of neuroblastoma therapy on survivors' growth, pubertal development and long-term health.

This grant is named for and funded by the "Just Do It...…and be done with it" Hero Fund created in honor of Sara Martorano who doesn't let anything dim her sparkle and has a compassionate heart and smile. It also celebrates the courage of all cancer kids through treatment and the support of their family and friends.

Developing new therapies from medicine to procedures is the best way to cure cancer and save lives. Clinical trials are research studies involving people of all ages to see if a new drug or medical device is safe and effective. One of the nation’s top children’s hospitals for cancer care, Lurie Children’s offers more pediatric clinical trials than any other hospital in the state. With more studies, their specialists have many options when treating a child with cancer. The success of a clinical trial depends on trained clinical research professionals (CRPs) to manage the study, from enrolling participants to reporting data in a timely and accurate manner. Like many healthcare professionals, CRPs are in high demand due to labor shortages and a very competitive marketplace. With more resources, we can better recruit, train and retain invaluable CRPs so we can provide every child with cancer access to innovative new therapies. This grant supports a clinical research coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The grant is named in honor of the Do It for Dominic Fund. This Hero Fund was created in memory of Dominic Cairo, who died from Non-Hodgkin Lymphoma at the age of 8. His family and friends continue to focus their efforts on raising funds and supporting St. Baldrick’s in the effort find cures for childhood cancers in the hopes that no child ever has to go through what Dominic had to endure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. The University of Illinois at Chicago (UIC), Rush University Medical Center, and John H. Stroger Hospital of Cook County COG Clinical Trials Program exists to meet the needs of an extremely diverse population of patients from birth to 30 years of age (and sometimes beyond) who are currently struggling with cancer or who have survived this terrible disease but are at great risk for many, many long term health problems. UIC, Rush and Stroger Medical Centers anchor the near west side of Chicago and serve incredibly vulnerable patients and families, with the majority of whom having very limited personal resources, medical knowledge, limited English language skills and who have no or public insurance.

This grant is named for the Do It for Dominic Fund which honors the memory of Dominic Cairo who battled non-Hodgkins lymphoma and was a hero to his school and community. His family and friends continue to raise funds and support research in the hopes that no child has to go through what Dominic endured.

Pediatric high-grade gliomas (pHGGs) are a fatal childhood cancer of the brain. Deregulation of specific histone modifications, both with and without a direct link to specific mutations, have been identified in these tumors. This project will investigate histone H3 post-translational modifications (PTMs) in pHGGs to advance our understanding of tumor development and understanding of biologic characteristics, and to promote the identification of effective therapies for improving the outcomes for patients with these tumors.

This grant is generously supported by The Benicio Martinez Fund for Pediatric Cancer Research, a St. Baldrick's Hero Fund created in honor of Benny's fight with cancer and supports cures and better treatments for kids like him. Weeks after being the top fundraiser in his 6th grade class and shaving his head at his school’s event, Benny was diagnosed with medulloblastoma. Since then he has had brain surgery, radiation and chemotherapy. Despite complications from treatment and setbacks, Benny has an amazing can-do attitude and is battling the cancer with courageous determination.

For a child is diagnosed with a diffuse intrinsic pontine glioma so called DIPG, the options for treatment are scarce and so are the chances for survival. This aggressive brain tumor generally strikes children who are 6 years old and younger, with most surviving less than a year after diagnosis. The only known effective treatment is the use of radiation. Yet, even with radiation therapy most children show tumor progression within the year after radiation therapy. Given this reality, there is a desperately need to identify the drug that increase the anti-tumor activity of radiation, as a mean to improve treatment outcome for these children. DNA damage is thought to be the most toxic effect caused by radiation, and Dr. Hashizume and others showed that the majority of the DNA damage caused by radiation are repaired within 24 hours of treatment. This DNA damage repair is possibly responsible for the tumor progression observed in DIPG after radiation therapy, thereby ultimately taking no survival benefits to the patients. As the recipient of the Just Do It...and be done with it St. Baldrick's Research Grant, Dr. Hashizume recently performed a genetic screening in DIPG cells collected from patient tumor and found specific therapeutic targets which is important for DNA damage repair. This research will study whether targeted inhibition of DNA damage repair increase DNA damage by radiation, leading to increased radiation toxicity in DIPG. Successful results from this research will find a new effective therapy which increases the anti-tumor activity of radiation, in turn, will ultimately leads to improved treatment outcomes for children with highly malignant and currently incurable cancer.

This grant is funded by and named for the “Just Do It…and be done with it” Hero Fund created in honor of Sara Martorano who was 4 when she was diagnosed with Stage IV Wilms tumor. Despite a grueling treatment protocol of surgeries, radiation and chemotherapy, Sara didn’t let anything dim her sparkle. Thanks to life-saving research, today she is cancer free. This fund celebrates the courage of all cancer kids enduring treatment and the support of their family and friends.

Awarded at Northwestern University and transferred to Ann & Robert H. Lurie Children's Hospital of Chicago.

This grant supports a clinical research coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports the Nurse Researchers in the UIC/Rush/Stroger COG Program to ensure more kids can be treated on clinical trials, often their best hope for a cure.

Cancer remains a major cause of death in children. It is still difficult to collect and share large samples of clinical trials data across research groups, because everyone collects the data according to their own preferences and definitions. This limits researchers' ability to use a patients' clinical data and to match it to data from new techniques, like genomic testing, to make discoveries. The Pediatric Cancer Data Commons (PCDC) designs better ways to collect and store these clinical data and to connect these data to other types of data, such as imaging data (x-rays, CT scans) and genomic data, by developing and documenting a common language and standards. This allows others to see how our researchers are collecting, storing, sharing, and using clinical trials data so that others can also conduct research in the same way and then easily share and compare data sets across the world. The PCDC Consortium members are dedicated to gathering as much data as possible from around the world into a "data commons" - a single place where researchers everywhere can go to access these data so that they can explore the data and select the subsets of data that are useful for answering their research questions. Fund administered by The University of Chicago.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

For children with pediatric brain tumors radiation therapy has been the backbone of treatment, in combination with surgery and chemotherapy. Although pediatric brain tumors can be highly responsive to radiation its use needs to be limited since radiation can be damaging to the brain, causing abnormal inflammation and long-term cognitive deficits that will profoundly impact the lives of patients. As the recipient of the Benicio Martinez Fund for Pediatric Cancer Research St. Baldrick's Research Grant, Dr. Sredni and her colleagues have identified a new drug (MW151) that can be given orally to patients receiving radiation therapy and can protect their brains against the cognitive decay caused by radiation. They are about to start a clinical trial, funded by the government (NIH/NCI), associating MW151 to whole brain radiation for the treatment of adults with brain metastases. Her goal is to move this approach to the pediatric population. This project is performing experiments that will test if inhibiting neuroinflammation with MW151 will interfere with brain tumor's response to radiation. This information is crucial to allow them to move forward with the studies necessary to use this protective drug in children. This new drug candidate has the potential to provide a safe and effective new adjunct protective treatment strategy. It can potentially transform the care and significantly improve the quality of life of our young patients and their families. Weeks after being the top fundraiser in his 6th grade class and shaving his head at his school’s event, Benny was diagnosed with medulloblastoma. Despite complications from treatment and setbacks, Benny has an amazing can-do attitude and is battling the cancer with determination.

This grant is funded by the Hero Fund that honors Benny’s fight and supports cures and better treatments for kids like him.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

Pediatric cancer research remains limited by a lack of data sharing. While clinical trials remain the cornerstone of pediatric cancer breakthroughs, a consistent and reliable way to store and share data from these trials is lacking. The University of Chicago Pediatric Cancer Data Commons was established to solve this important problem. Sitting alongside the NCI's Genomic Data Commons, the PCDC serves as a neutral repository for data from clinical trials. This information is first converted into a commons format that is consistent across pediatric cancers. The PCDC allows researchers to search over thousands of patients' data to see quickly what data are available for study. Researchers can then apply for access to data, and the PCDC streamlines the process of requesting and downloading data. Finally, the PCDC connects researchers to other kinds of data, including genomic information so critical to studying pediatric cancer. This grant supports personnel to help build the PCDC, so that researchers can efficiently access data and create new ways to study pediatric cancer.

This grant supports the Nurse Researchers in the UIC/Rush/Stroger COG Program to ensure more kids can be treated on clinical trials, often their best hope for a cure.

Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant brain tumor that has a very poor prognosis despite aggressive treatment. The development of new, effective therapeutic approaches for AT/RT has been hindered by a lack of specific therapeutic targets. It is necessary to find effective therapeutic targets, preferably based on the understanding of the molecular mechanisms that promote this highly malignant brain tumor. A tumor suppressor gene (SMARCB1) is absent in the majority of AT/RT and loss of this gene leads to factors that promote tumor growth. This research involving genetic and pharmacologic inhibition of histone binding proteins (EZH2 and BRD4) is of high importance for developing effective therapies for pediatric patients with AT/RT. Dr. Hashizume will determine whether therapeutic combination of targeting two histone binding proteins, BRD4 and EZH2, provides synergistic benefits, and will inform how best to maximize the clinical potential of combination therapy for effective treatment of children with AT/RT. This research will also test how tumors adapt to this molecular targeted therapy, to ultimately inform clinicians how to treat tumors that have resistance to molecular targeted therapy. Finally, this project will explore how this combination therapy interacts with radiation in treating AT/RT, which is important due to the frequent use of radiation in treating AT/RT.

This grant is generously supported by the “Just Do It…and be done with it” St. Baldrick’s Hero Fund created in honor of Sara Martorano who was four years old when she was diagnosed with Stage IV Wilms tumor. Thanks to research, today she is cancer free. This fund celebrates the courage of cancer kids through treatment and the support of their family and friends.